Queen asked if anyone wanted to live forever. The answer used to be a shrug. Now, it looks like a hard mathematical no.
New research from the Skolkovo Institute of Science suggests that even if we magically cured cancer, heart disease, and dementia, humans still wouldn’t achieve immortality. A hard cap exists. Most people would still hit a wall at 150 to 199 years.
That’s roughly double what we manage today—the current average lifespan hovers around 79 years globally. But doubling it isn’t infinite. It’s a limit. And it stems from one unsexy, unavoidable biological fact: DNA gets sloppy.
The Genetic Drift That Breaks Us
As we age, our cells divide. Every division is a gamble. Tiny mistakes creep into our genetic code. We call these somatic mutations.
Most of the time, our bodies repair these errors. It’s a robust system. But it’s not perfect.
Over decades, these mutations accumulate. They’re random. Most are harmless bystanders. But a few? They’re trouble. They drive cancer. They wreck tissue function.
Here’s the kicker from the new study led by computational biologist Dmitrii Kriuki. Imagine a world where every age-related disease is eradicated. No cancer. No Alzheimer’s. No heart failure.
Would you live forever?
The math says no.
The researchers built a model to simulate this hypothetical scenario. They wanted to know if random DNA mutations alone could impose a ceiling on longevity. The result was startling. Even in this utopia, the mutations would eventually overwhelm cellular function.
The body stops working. Not from a single disease, but from cumulative genetic static.
How Long Can We Actually Live?
The study didn’t just guess. They quantified it.
Using a mathematical framework published in npj Aging, the team modeled how mutation rates impact major organs. They didn’t predict the future of human lifespan in a practical sense. This was a thought experiment. A stress test for biology.
The numbers varied slightly by model, but the range was consistent: 146 to 199 years.
Median lifespan sat around 150 to 160 years.
Some outliers might push past 190. But 200? 300? Unlikely under this framework. The mutations accumulate too fast for the body to sustain function indefinitely.
“This is a mathematical estimate (though careful),” Kriukov noted. It’s not a verdict. But it highlights that somatic mutations are a critical, albeit weak, driver of aging on their own.
Which Organs Fail First?
Not all cells are created equal.
Tissues like skin and liver are workhorses. They replace themselves constantly. Old cells die. New ones take their place. This rapid turnover can theoretically continue for centuries, provided the DNA remains clean.
But the heart and brain? Different story.
These organs rely on long-lived cells. Neurons and cardiomyocytes rarely divide. They stick around for decades. And because they don’t get replaced, they accumulate mutations over time without the buffer of renewal.
These resilient cells become the bottleneck. They bear the brunt of the genetic damage. And eventually, they fail. That’s where the 150-year limit comes from—not the whole body breaking down, but the key systems running on corrupted code.
Why This Matters for Longevity Science
For years, scientists have debated the somatic mutation theory of aging. Does DNA drift cause aging? Or is it just a side effect?
This study suggests mutations are necessary but not sufficient.
If mutations alone cap us at 150 years, but humans currently max out much lower, other factors are at play. Inflammation? Telomere shortening? Mitochondrial decay? The list is long.
The study doesn’t dismiss these other mechanisms. It isolates one variable to show its impact. By doing so, it creates a framework to measure how much each process contributes.
This is crucial for drug development. If you’re trying to slow aging, you need to know which lever to pull. Is it reducing mutations? Or targeting protein misfolding?
The research reinforces a simple truth: aging is complicated. It’s not one switch. It’s a symphony of failures.
The Path Forward
Solving aging won’t happen in isolation.
Kriukov and his team emphasize that this is just the first step. Dissecting aging into quantifiable parts is hard work. It requires coordination across genetics, computer science, and clinical trials.
“Ultimately, incorporating other major aging factors could pavethe way to a comprehensive, mechanistic theory,” they write.
We’re not getting forever. The DNA won’t allow it. But understanding the exact mechanics of why we die at 80, rather than 150, might still buy us some extra time.
The limit is there. The question is whether we can live close to it.
“Achieving it would require coordinated efforts… a challenging but increasingly attainable prospect.”
Maybe. Or maybe the mutations win anyway. One day, we’ll know. Until then, we keep counting.
